Physician profile
Gerald Morris
NPI 1871559864
$1,281.71
in general payments reported to CMS, 2019-2025
20 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.22 · 2023: $166 · 2024: $480 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.94 | 2023-2025 | |
| Exact Sciences Corporation | $132.83 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $124.84 | 2023-2025 | |
| Lilly USA, LLC | $112.90 | 2023-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $96.47 | 2025 | Auvelity |
| Gilead Sciences, INC. | $80.95 | 2023-2024 | |
| Astellas Pharma US INC | $76.98 | 2025 | Veozah |
| Dexcom, INC. | $76.23 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $67.88 | 2022-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Corcept Therapeutics | $67.21 | 2025 | Korlym |
| Novo Nordisk INC | $48.81 | 2023-2025 | Ozempic, Rybelsus |
| Amgen INC. | $41.45 | 2024-2025 | Repatha, Otezla, Repatha |
| Phadia US INC. | $39.10 | 2022-2024 | Immunocap |
| Viiv Healthcare Company | $32.28 | 2023 | Apretude |
| Baxter Healthcare | $22.46 | 2023 | Hillrom - Life 2000 Ventilation System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $20.01 | 2024 | Gvoke Hypopen |
| Cranial Technologies, INC | $19.25 | 2024 | Doc Band |
| Pfizer INC. | $16.77 | 2023 | |
| Braeburn INC. | $16.44 | 2025 | Brixadi |
| Alkermes, INC. | $15.91 | 2024 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.